Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science
Yasser Fouad(Minia University), Puneet S. Arora(Beth Israel Deaconess Medical Center), Richard Torstenson(Kansas City Research Institute), Steven Bollipo, Henrik Landgren(National Center for Toxicological Research), Minjun Chen(National Center for Toxicological Research), Rajarshi Banerjee(John Radcliffe Hospital), Dina Attia(Boehringer Ingelheim (Germany)), M.A. Karsdal(Nordic Bioscience (Denmark)), Bradley Freilich(Kansas City Research Institute), Robert Riccio(Syneos Health (United States)), Arie Regev, Д. А. Шапиро(Cleveland Clinic), Melissa Palmer(ABS Consulting (United States)), Alastair D. Smith(Duke Medical Center), Martin I. Blake(Oxford Medical Diagnostics (United Kingdom)), Hans-Juergen Gruss(Syneos Health (United States)), Rob Myers(John Hunter Hospital), Muhammad Y. Sheikh(AstraZeneca (United Kingdom)), Ramy Younes(University of Turin)
Figshare
January 1, 2022
Cited by 14
Related Papers
Liver biopsy†
|Hepatology|2008|1.9k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
|Hepatology|2015|689
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease
|Journal of Hepatology|2013|481